Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 47 of 47 matching drugs for DNMT1 — including drugs targeting any of its 41 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab DNMT1 Direct 1
decitabine, gemcitabine DNMT1 Direct 1
e. coli cd-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium, pharmacological study, laboratory biomarker analysis DNMT1 Direct 1
flucytosine, polymerase chain reaction, immunohistochemistry staining method, gene therapy, pharmacological study, 3-tesla magnetic resonance imaging, laboratory biomarker analysis, therapeutic conventional surgery, e. coli cd-expressing genetically modified neural stem cells DNMT1 Direct 1
ft-2102, azacitidine, nivolumab, gemcitabine and cisplatin DNMT1 Direct 1
pembrolizumab, azacitidine DNMT1 Direct 1
romidepsin, azacitidine, nab-paclitaxel, gemcitabine, durvalumab, lenalidomide capsule DNMT1 Direct 1
sx-682, decitabine DNMT1 Direct 1
tetrahydrouridine, decitabine DNMT1 Direct 1
azacitidine DNMT1 Direct yes 0
decitabine DNMT1 Direct yes 0
adagrasib KRAS SSL via KRAS yes 2
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
sotorasib KRAS SSL via KRAS yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
osimertinib EGFR SSL via EGFR yes 1
melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells HTR3C SSL via HTR3C 2
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) PIK3R1 SSL via PIK3R1 1
enzastaurin, lomustine PIK3R1 SSL via PIK3R1 1
enzastaurin, temozolomide, radiation therapy PIK3R1 SSL via PIK3R1 1
ethanol, enoxaparin HTR3C SSL via HTR3C 1
gabapentin, sulfasalazine, memantine, temozolomide, radiotherapy NFKB2 SSL via NFKB2 1
sulfasalazine NFKB2 SSL via NFKB2 1
afatinib dimaleate EGFR SSL via EGFR yes 0
amisulpride HTR3C SSL via HTR3C yes 0
ataluren RPL22 SSL via RPL22 yes 0
cetuximab EGFR SSL via EGFR yes 0
clothiapine HTR3C SSL via HTR3C yes 0
dexfenfluramine HTR3C SSL via HTR3C yes 0
dexfenfluramine hydrochloride HTR3C SSL via HTR3C yes 0
erlotinib hydrochloride EGFR SSL via EGFR yes 0
lapatinib EGFR SSL via EGFR yes 0
lapatinib ditosylate EGFR SSL via EGFR yes 0
midostaurin PRKCZ SSL via PRKCZ yes 0
necitumumab EGFR SSL via EGFR yes 0
neratinib EGFR SSL via EGFR yes 0
neratinib maleate EGFR SSL via EGFR yes 0
osimertinib mesylate EGFR SSL via EGFR yes 0
panitumumab EGFR SSL via EGFR yes 0
regorafenib EGFR SSL via EGFR yes 0
tropisetron HTR3C SSL via HTR3C yes 0
vandetanib EGFR SSL via EGFR yes 0
zimeldine HTR3C SSL via HTR3C yes 0
zimeldine hydrochloride HTR3C SSL via HTR3C yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.